Boxer Capital’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-4,207,086
| Closed | -$5.55M | – | 78 |
|
|
2022
Q1 | $5.55M | Hold |
4,207,086
| – | – | 0.29% | 53 |
|
|
2021
Q4 | $5.68M | Sell |
4,207,086
-1,400,000
| -25% | -$3.31M | 0.22% | 53 |
|
|
2021
Q3 | $16.3M | Hold |
5,607,086
| – | – | 0.57% | 51 |
|
|
2021
Q2 | $19.6M | Hold |
5,607,086
| – | – | 0.69% | 46 |
|
|
2021
Q1 | $19.2M | Hold |
5,607,086
| – | – | 0.65% | 44 |
|
|
2020
Q4 | $108M | Buy |
5,607,086
+400,000
| +8% | +$6.17M | 3.46% | 7 |
|
|
2020
Q3 | $69.9M | Buy |
5,207,086
+1,843,709
| +55% | +$52.2M | 2.42% | 9 |
|
|
2020
Q2 | $142M | Hold |
3,363,377
| – | – | 6.26% | 4 |
|
|
2020
Q1 | $92.9M | Hold |
3,363,377
| – | – | 6.33% | 4 |
|
|
2019
Q4 | $109M | Hold |
3,363,377
| – | – | 6.17% | 4 |
|
|
2019
Q3 | $87.5M | Hold |
3,363,377
| – | – | 6.35% | 5 |
|
|
2019
Q2 | $123M | Buy |
3,363,377
+384,615
| +13% | +$9.22M | 10.61% | 2 |
|
|
2019
Q1 | $65.9M | Hold |
2,978,762
| – | – | 7.62% | 4 |
|
|
2018
Q4 | $41.9M | Buy |
2,978,762
+151,824
| +5% | +$2.36M | 5.18% | 8 |
|
|
2018
Q3 | $54.9M | Hold |
2,826,938
| – | – | 6.09% | 7 |
|
|
2018
Q2 | $62.4M | Hold |
2,826,938
| – | – | 7.07% | 5 |
|
|
2018
Q1 | $59.9M | Buy |
2,826,938
+100,000
| +4% | +$2.36M | 6.39% | 5 |
|
|
2017
Q4 | $68.2M | Buy |
+2,726,938
| New | +$64.4M | 12.46% | 2 |
|
Boxer Capital's ODT Position: Q2 2022 in Review
Boxer Capital sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2022, closing a stake of 4,207,086 shares — an estimated $5.55M sold.
Boxer Capital first reported a position in ODT in Q4 2017 and held it in 18 quarters. The position peaked at $142M in Q2 2020. 0 funds tracked by Wall St. Rank hold ODT as of Q2 2022.
- Boxer Capital reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
- Boxer Capital sold 4,207,086 Odonate Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $5.55M.
- Boxer Capital first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 18 quarters.
- Boxer Capital's Odonate Therapeutics, Inc. Common Stock position peaked at $142M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2022.
Based on Boxer Capital's 13F filing for Q2 2022, filed 15 Aug 2022.